Trevi Therapeutics(TRVI) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET New Haven, Conn., August 7, 2025 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company deve ...